CAMBRIDGE, Mass. & PHILADELPHIA, Pa. – August 28, 2026 – Nava Therapeutics CEO Federico Mingozzi, Ph.D., discusses the advances in ionizable lipid chemistry fueling investment in in vivo CAR-T, how the company’s proprietary lipid nanoparticle (LNP) platform delivers RNA therapies to tissues beyond the liver, and Nava’s evolution from a delivery platform into a company advancing its own pipeline of in vivo CAR-T cell and RNA therapies for autoimmune diseases and other therapeutic areas.
Read more in the U.S. Pharmaceutical Industry Weekly Report
About Nava Therapeutics
Nava Therapeutics is a biotechnology company developing a new generation of genetic medicines through precision RNA delivery. By combining rational lipid design with high-throughput discovery, Nava has built a proprietary LNP platform capable of selectively targeting cells and tissues beyond the liver.
Business Development contact
For partnership, licensing, or collaboration inquiries, please reach out to bd@navatx.com.
General Inquiries contact
For all other inquiries, please reach out to info@navatx.com.